EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia Academic Article uri icon

abstract

  • The human EphA3 gene was discovered in a pre-B acute lymphoblastic leukemia (pre-B-ALL) using the EphA3-specific monoclonal antibody (mAb), IIIA4, which binds and activates both human and mouse EphA3. We use two models of human pre-B-ALL to examine EphA3 function, demonstrating effects on pre-B-cell receptor signaling. In therapeutic targeting studies, we demonstrated antitumor effects of the IIIA4 mAb in EphA3-expressing leukemic xenografts and no antitumor effect in the xenografts with no EphA3 expression providing evidence that EphA3 is a functional therapeutic target in pre-B-ALL. Here we show that the therapeutic effect of the anti-EphA3 antibody was greatly enhanced by adding an α-particle-emitting 213Bismuth payload.

authors

  • Charmsaz, S
  • Al-Ejeh, F
  • Yeadon, TM
  • Miller, KJ
  • Smith, FM
  • Stringer, BW
  • Moore, AS
  • Lee, Fook-Thean
  • Cooper, LT
  • Stylianou, C
  • Yarranton, GT
  • Woronicz, J
  • Scott, Andrew M
  • Lackmann, M
  • Boyd, AW

publication date

  • 2017